A Hormone Therapy Guide for Vasomotor Symptoms

Understand how vasomotor symptoms and cardiometabolic risk can influence your health and the role of hormone therapy.

Abstract

In this educational post, I guide you through a clear, first-person journey into the physiology and treatment of menopausal symptoms, particularly vasomotor symptoms (VMS), including hot flashes and night sweats. I explain the hypothalamic-pituitary-ovarian (HPO) axis, the roles of key hormones like estrogen and progesterone, and the neuroendocrine mechanisms involving KNDy neurons that narrow the body’s thermoregulatory zone. I present a comprehensive overview of modern, evidence-based management options, including the benefits, risks, and contraindications of hormone therapy (HT), non-hormonal pharmacotherapies, and mind-body approaches. I emphasize individualized, shared decision-making and show how we integrate chiropractic care, functional medicine, lifestyle interventions, and personal injury rehabilitation to improve outcomes. Finally, I introduce a key enhancement to our care model: Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), who serves as Medical Director and Collaborative Physician alongside me at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, ensuring a robust, multidisciplinary approach to women’s health.

A Patient’s Question That Opens the Door

When a patient looks at me and asks, “Am I going to deal with this until I die? Is there anything I can do to reduce these hot flashes? Do you have any medicines for me?” I hear both urgency and hope. I regularly meet women who say, “I woke up in a hot blanket, drenched in sweat, and I feel yucky.” When those words come from a 52-year-old scientist who has not menstruated for 15 months, I know we are likely facing vasomotor symptoms (VMS) related to menopause.

That moment is an opportunity to educate, reassure, and co-create a plan. If you are a primary care clinician or a patient navigating these changes, this post is written to be easy to read and clinically practical. I present the latest findings from leading researchers using modern, evidence-based methods and show how we integrate chiropractic care, functional medicine, and medical oversight into a cohesive plan.

Our Multidisciplinary Team: Dr. Jimenez and Dr. Cardenas Together

At Injury Medical Clinic PA in El Paso, Texas, we operate from a foundational belief: that the most effective patient care is never delivered in a silo. That is why I am proud to announce that Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933), with over 40 years of experience as an internist, has joined our team as Medical Director and Collaborative Physician.

This multidisciplinary setup is a best-practice model in integrative and injury care settings. It brings together the medical authority and diagnostic breadth of an internal medicine physician with the musculoskeletal, neuromuscular, and functional medicine expertise of a chiropractor and advanced practice nurse practitioner. For our patients, this means seamless, coordinated care that addresses the full spectrum of their health needs.

What This Collaborative Model Offers Patients

• Medical oversight from Dr. Cardenas, including comprehensive risk assessment for hormone therapy, management of chronic diseases, hormonal conditions, cardiovascular risk, and complex comorbidities.
• Chiropractic and neuromusculoskeletal care from me, Dr. Jimenez, addressing spinal health, nervous system function, and biomechanical factors that influence overall wellness.
• Functional medicine evaluations to identify root causes of hormonal imbalance, metabolic dysfunction, and inflammation.
• Personal injury care and rehabilitation, supporting patients whose musculoskeletal strain exacerbates sleep and VMS, or those recovering from accidents and trauma.
• Advanced practice nursing services, including prescription management, hormone therapy oversight, and patient education.

When it comes to menopause management, this model is particularly powerful. Dr. Cardenas brings decades of internal medicine wisdom and clinical precision. In contrast, I bring a functional, integrative lens that considers the whole body—including the spine, nervous system, gut health, and lifestyle factors—and how these factors influence a woman’s experience of and recovery from menopause.

Case Start: Meeting Miss Jenny and Framing the Clinical Questions

To illustrate our approach, let’s consider a pleasant 52-year-old woman, “Miss Jenny.” She recently relocated and now wakes multiple times at night in what feels like a “hot blanket.” These episodes have intensified over two years, and her last menstrual period was 15 months ago, placing her in postmenopause by standard definition.

When I encounter this story, I begin with a thorough assessment:

• Menstrual history: Cycle length changes, duration of amenorrhea, and bleeding patterns.
• Symptom inventory: VMS, sleep disturbance, mood, genitourinary complaints, sexual function, cognition, and joint pain.
• Prior treatments: What has been tried, what helped or harmed, and any side effects.
• Personal and family history: Cardiovascular risk, bone health, cancer risks, migraine with aura, venous thromboembolism, and smoking.
• Medication and supplement review: SSRIs/SNRIs, clonidine, gabapentin, herbal agents, OTC sleep aids, and alcohol/caffeine use.
• Physical exam: Vitals, BMI, thyroid palpation, cardiopulmonary, breast, abdominal, pelvic (when appropriate), and a musculoskeletal assessment for posture and mobility.

Defining Menopause and Its Timeline

Menopause is clinically defined by the final menstrual period followed by no menstruation for 12 months. It results from the loss of ovarian follicular function within the hypothalamic-pituitary-ovarian (HPO) axis. In the United States, the median age is roughly 52.5 years. Key variants include:

• Early menopause: Before age 45.
• Late menopause: After age 54–55.
• Premature menopause: Before age 40.

It’s crucial to understand that menopause is not just a genitourinary event; it profoundly affects the skeletal, cardiovascular, and nervous systems. Recognizing this helps clinicians anticipate and mitigate longer-term health risks.

I often simplify the staging for patients:

• Reproductive phases (early to late): Cycles are typically regular, with subtle changes emerging in the late reproductive phase.
• Menopausal transition (perimenopause): Characterized by cycle variability of ≥7 days, then intervals of ≥60 days or skipped cycles. This is when symptoms often appear.
• Postmenopause: Begins 12 months after the final menstrual period. Symptoms may persist or evolve.

While biomarkers can be helpful, clinical history remains paramount. Follicle-stimulating hormone (FSH) can be variable but typically rises during the late transition, often above 25 IU/L, before stabilizing a couple of years postmenopause. However, routine hormone testing is not required for average-age menopause when the clinical picture is clear.

The Physiology Behind Menopausal Symptoms

To explain VMS well, I walk patients through the hormonal dynamics. The decline in ovarian follicles triggers a cascade:

• Inhibin: This hormone normally inhibits pituitary FSH. With less inhibin, FSH increases, often fluctuating widely.
• Progesterone falls due to less frequent ovulation, contributing to cycle irregularity.
• Estrogen transitions from estradiol (E2) dominance premenopause to estrone (E1) postmenopause, as E1 is produced more from adrenal and adipose tissue.
• Testosterone generally decreases but often remains within normal female ranges.

These hormonal shifts underpin a cascade of physiological changes across systems.

Why Hot Flashes Happen: Thermoregulation and the Hypothalamus

Here is the neuroendocrine story in plain terms. Hot flashes and night sweats—the hallmark vasomotor symptoms—stem from shifts in the central thermoregulatory network. As ovarian estrogen production declines, the brain’s temperature-regulation center—the hypothalamus—becomes more reactive and hypersensitive.

• The thermoneutral zone: In healthy, nonmenopausal states, small changes in body temperature do not trigger cooling responses. Postmenopause, tiny temperature shifts may trigger peripheral vasodilation and diaphoresis (sweating), which are felt as hot flashes.
• Estrogen’s modulation of KNDy neurons (kisspeptin, neurokinin B, dynorphin) is central to this process. Estrogen normally dampens neurokinin B (NKB) stimulation of these neurons. Low estrogen permits unopposed NKB activity, increasing hypothalamic excitability. This hyperactivity is linked to changes in LH pulses and symptomatic vasomotor events. Dysregulation here contributes to the frequency and severity of symptoms, sleep fragmentation, mood changes, and reduced daytime function (Freedman, 2014; Parish et al., 2019).
• Neuroregulatory pathways involving serotonin and norepinephrine also modulate thermoregulation, which is why SSRIs/SNRIs can reduce VMS frequency and severity.

More than 80% of women experience VMS, and for about half, they may last over seven years. They frequently occur at night, disrupting sleep. In my practice observations, captured on PushAsRx and through my clinical updates on LinkedIn, I find that restoring circadian rhythm, reducing systemic inflammation, and supporting autonomic balance can materially improve symptom burden alongside targeted medical therapy.

Evidence-Based Treatment Options for Menopause

Our management plan depends on symptom burden, quality of life, comorbidities, risk profile, and patient goals. With Dr. Cardenas’s medical oversight, we stratify cardiovascular and breast cancer risk, assess bone health, and evaluate thromboembolic history before initiating any therapy.

The Benefits of Hormone Therapy: What the Evidence Shows

Modern, evidence-based research has substantially refined our understanding of hormone therapy. The blanket fears that followed the 2002 Women’s Health Initiative study have been significantly re-contextualized, and newer research using transdermal and bioidentical formulations has painted a far more nuanced and encouraging picture.

• Relief of vasomotor symptoms: Hormone therapy remains the most effective intervention for moderate-to-severe hot flashes and night sweats, restoring sleep quality and daytime functioning.
• Genitourinary symptom relief: Estrogen deficiency leads to vulvovaginal atrophy, causing painful intercourse (dyspareunia), urinary urgency, and recurrent UTIs. Local vaginal estrogen addresses these symptoms with minimal systemic absorption.
• Cardiovascular protection when initiated early: When HT is started within ten years of menopause onset or before age 60, evidence supports a cardioprotective effect. This is known as the “timing hypothesis”. Estrogen preserves endothelial function, supports lipid metabolism, and reduces vascular inflammation.
• Reduced risk of type 2 diabetes: Research supports that hormone therapy is associated with a lower risk of developing type 2 diabetes, likely by improving insulin sensitivity.
• Cognitive and mood support: Estrogen’s decline is associated with depression, irritability, and brain fog. HT, particularly when initiated during the perimenopausal window, may reduce these burdens.
• Bone protection: Estrogen is a critical inhibitor of osteoclast activity (bone resorption). HT helps preserve bone mineral density and reduce fracture risk.

Why We Use Systemic Estrogen Therapy

Systemic estrogen re-expands the thermoneutral zone and stabilizes hypothalamic signaling by re-engaging the inhibition of NKB stimuli on KNDy neurons. This reduces the sympathetic vasodilatory surges that create hot flashes. For women with a uterus, a progestogen is required to protect the endometrium.

Why Transdermal Estradiol Is Often First-Line

Transdermal estradiol (patches, gels, mists) delivers hormone directly into circulation, bypassing the liver. This lowers the impact on clotting factors and triglycerides compared to oral estrogens. In my practice, transdermal options are frequently my first choice because they:

• Provide stable serum estradiol levels.
• Reduce the risk of venous thromboembolism relative to oral formulations.
• Improve adherence with simple dosing schedules.

Oral and Parenteral Hormone Therapy

Oral estrogen is appropriate for some patients, particularly those who have had a hysterectomy. We can also use oral combination pills. Parenteral (injectable) estradiol may be considered in severe cases. In all instances, if a uterus is intact, progestin coverage is essential. I frequently prefer micronized progesterone for its favorable absorption and tolerability profile.

Non-Hormonal Medications

When hormones are contraindicated or declined, we turn to effective non-hormonal options:

• SSRIs/SNRIs (e.g., paroxetine, venlafaxine): These modulate central thermoregulatory pathways via serotonergic/noradrenergic signaling. Central serotonergic balance improves the hypothalamic threshold against small core temperature fluctuations.
• Gabapentin: Through central calcium channel modulation, it dampens neuronal hyperexcitability, which often manifests as nighttime VMS.
• NK3 Receptor Antagonists (NK3RAs): Drugs such as fezolinetant directly target the neurokinin B pathway, resulting in significant reductions in hot flash frequency and severity (Prähst et al., 2023; Fraser et al., 2024).

---

Aligned & Empowered: Chiropractic Conversations on Women’s Health- Video

---

Mind-Body Therapies and Complementary Approaches

• Cognitive Behavioral Therapy (CBT): Evidence supports its use to reduce hot flash severity, improve coping, and enhance sleep quality. It recalibrates cognitive and behavioral responses to flashes, reducing distress (Ayling et al., 2016).
• Clinical Hypnosis: Promising evidence suggests it reduces VMS and improves sleep by modulating autonomic reactivity and easing thermoregulatory instability (Elkins et al., 2013).

Lifestyle and Functional Medicine Strategies

Functional medicine helps us identify contributors that worsen VMS:

• Sleep and circadian disruption: Consistent sleep-wake windows and light exposure hygiene stabilize hypothalamic rhythms.
• Inflammation and insulin resistance: Anti-inflammatory nutrition, protein adequacy, and resistance training reduce triggers for flashes.
• Stress physiology: Mindfulness, CBT, and biofeedback restore vagal tone.
• Thermoregulation tactics: Layered clothing, cooling bedding, and paced respiration buffer acute episodes.

How Integrative Chiropractic Care Fits Into Menopause Management

Many clinicians overlook the role of the musculoskeletal and nervous system in the menopausal experience. As a chiropractor and nurse practitioner, my clinical experience shows three key domains where integrative chiropractic care helps:

• Musculoskeletal modulation to assist thermoregulation: The autonomic nervous system, which governs vasomotor responses, is directly influenced by spinal alignment and neurological function. Gentle adjustments, particularly to the cervical and upper thoracic spine, soft tissue mobilization, and postural correction can reduce sympathetic dominance and muscle tension that amplify the subjective impact of hot flashes. Mechanotransduction from spinal joints modulates autonomic output via dorsal horn and supraspinal pathways.
• Sleep and pain improvement: VMS often coincides with neck and back tension and myofascial pain that fragment sleep. Targeted chiropractic rehabilitation—myofascial release, thoracic outlet mobilization, and diaphragmatic breathing coaching—improves comfort and can indirectly reduce nocturnal arousals.
• Exercise prescription and safe progression: Hormonal shifts alter connective tissue and neuromuscular tone. We use individually tailored programs of graded walking, resistance work, and mobility drills to build resilience without abruptly spiking core temperature. This also supports skeletal loading, which is one of the most effective non-pharmacological stimuli for preserving bone mass.

Adverse Effects, Risks, and Contraindications of Hormone Therapy

Shared decision-making depends on transparency. Every patient deserves a clear, honest, and individualized conversation about the known risks.

• Stroke and Venous Thromboembolism (VTE): Both estrogen-only and combined HT increase risk, primarily with oral formulations due to their effect on hepatic clotting factors. Transdermal estrogen significantly reduces this risk and is preferred in patients with any VTE risk factors.
• Endometrial Cancer: In women with an intact uterus, unopposed estrogen dramatically increases this risk. This is why micronized progesterone or another progestin must be prescribed alongside estrogen.
• Breast Health Considerations: The risk profile is complex. Estrogen-only therapy carries the lowest risk. Combined estrogen-progestin therapy increases associated risks after three to five years, though the use of micronized progesterone appears to confer a lower risk than synthetic progestins.
• Gallbladder Disease: A modest increase in risk, primarily with oral formulations.
• Cardiovascular Disease in Older Women: Women over age 60 or more than ten years post-menopause face an elevated cardiovascular risk if hormone therapy is initiated de novo.

Conditions Requiring Special Caution or Avoidance

• Current or past breast issues: Always collaborate with the patient’s oncologist.
• Undiagnosed post-menopausal vaginal bleeding: HT must be suspended pending evaluation.
• Active or recent arterial thrombotic disease (e.g., stroke, heart attack).
• Untreated hypertension or uncontrolled cardiovascular disease.
• Active liver disease.
• Migraines with aura.

Monitoring Patients on Hormone Therapy: A Clinical Protocol

Safe and effective management requires diligent, ongoing monitoring.

• Six-Week Follow-Up: We assess early tolerability, symptom relief, and any initial side effects, such as vaginal spotting (which is common and typically resolves).
• Annual and Follow-Up Monitoring Checklist:

• • Symptom reassessment to establish the minimum effective dose.
  • Side effect screening (breast tenderness, bloating, headaches).
  • Pelvic examination and clinical breast exam.
  • Pap smear and mammography per guidelines.
  • Bone density screening (DEXA scan) for at-risk patients.
  • Cardiovascular risk assessment (blood pressure, lipid panel, fasting glucose).
  • Liver function tests for patients on oral estrogens.

Putting It All Together: Miss Jenny’s Journey

Returning to our patient, Miss Jenny, her integrative pathway would look like this:

1. Initial evaluation: A comprehensive history, risk review, and musculoskeletal assessment.
2. Shared Decision-Making: We explain the benefits and risks of all options. She is a good candidate for HT.
3. First-line therapy: We initiate a low-dose transdermal estradiol patch and oral micronized progesterone to protect the endometrium.
4. Adjuncts: We add CBT strategies for hot flash distress, diaphragmatic breathing drills, thoracic mobilization, and an anti-inflammatory nutrition plan with strength training.
5. Follow-up: We track her symptoms and titrate her estradiol dose at 4- 8 weeks.
6. Outcomes: The goal is decreased hot flash severity, improved sleep, better mood, and safer long-term bone and cardiovascular health.

When Miss Jenny asks, “Will this ever go away?” I explain that while many women see improvement over several years, our integrated approach aims to reduce symptom burden quickly while building resilience for the long term. With medical oversight from Dr. Cardenas and coordinated care at Injury Medical Clinic PA, we can safely trial therapies and pivot based on her responses and preferences.

Key Takeaways

• Vasomotor symptoms arise from complex neuroendocrine changes as estrogen declines, narrowing the thermoneutral zone and increasing hypothalamic excitability via KNDy neurons.
• Systemic estrogen with appropriate progestogen (if uterus intact) remains the most effective therapy for moderate-to-severe VMS; non-hormonal options like SSRIs/SNRIs and NK3RAs are strong alternatives.
• Integrative chiropractic care, functional medicine, and lifestyle interventions are powerful adjuncts that address sleep, stress, posture, and autonomic balance.
• The addition of Maria Guadalupe Cardenas, MD, as Medical Director strengthens our safety, diagnostics, and long-term health strategies.
• Individualized, shared decision-making ensures patients like Miss Jenny receive care aligned with their biology and values.

References

• ACOG Practice Bulletin: Management of Menopausal Symptoms (2022)
• Ayling, K., et al. (2016). Cognitive behavioral therapy for menopausal symptoms: A systematic review. Maturitas.
• Boardman, H. M. P., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B. (2015). Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews, 2015(3), CD002229.
• Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Levesque, H., Trillot, N., Barrellier, M. T., Wahl, D., Emmerich, J., & Scarabin, P. Y. (2007). Hormone therapy and venous thromboembolism among post-menopausal women: Impact of the route of estrogen administration and progestogens. Circulation, 115(7), 840–845.
• Cosman, F., et al. (2014). Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis International.
• Elkins, G., et al. (2013). Hypnosis for hot flashes: A randomized clinical trial. Menopause.
• Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Cancer Causes & Control, 19(7), 753–765.
• Fraser, G., et al. (2024). Fezolinetant for vasomotor symptoms: Clinical efficacy and safety. Journal of Women’s Health.
• Freedman, R. R. (2014). Menopausal hot flashes: Mechanisms, endocrinology, treatment. The Journal of Steroid Biochemistry and Molecular Biology, 142, 115- 120.
• Jimenez, A. (2026). Clinical observations in integrative and functional medicine. PushAsRx Clinical Platform.
• Jimenez, A. (2026). Professional practice and clinical insights. LinkedIn: Dr. Alex Jimenez, DC, APRN, FNP-BC.
• L’Hermite, M. (2017). Bioidentical hormones: Transdermal estradiol and micronized progesterone, the optimal route. Climacteric.
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., … & Wallace, R. B. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–1368.
• NICE guideline NG23: Menopause: diagnosis and management.
• Parish, S. J., et al. (2019). Comprehensive care of menopausal symptoms. The Journal of Sexual Medicine.
• Pinkerton, J. V., & Conner, E. A. (2019). Tissue-selective estrogen complex for menopausal therapy. Menopause.
• Sturdee, D. W., & Panay, N. (2010). Recommendations for the management of post-menopausal vaginal atrophy. Climacteric, 13(6), 509–522.
• The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The Menopause Society. Menopause, 29(7), 767–794.
• The North American Menopause Society (2023). Position statement: The 2023 hormone therapy update.

Disclaimer

This educational post was prepared by Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, in collaboration with Dr. Maria Guadalupe Cardenas, MD, at Injury Medical Clinic PA, El Paso, Texas. It is intended for educational purposes only and does not constitute individualized medical advice. Please consult a qualified healthcare provider for personalized clinical guidance.

SEO tags: menopause hormone therapy, perimenopause treatment El Paso, integrative menopause care, estrogen therapy benefits and risks, transdermal estrogen safety, micronized progesterone, vasomotor symptoms treatment, hot flashes night sweats, KNDy neurons thermoneutral zone, genitourinary syndrome of menopause, chiropractic care and menopause, functional medicine menopause, Dr. Alex Jimenez DC APRN, Dr. Maria Cardenas MD El Paso, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, shared decision making hormone therapy, osteoporosis menopause prevention, breast cancer risk hormone therapy, endometrial cancer estrogen, menopause and cardiovascular disease, evidence-based women’s health, multidisciplinary menopause care, hormone therapy monitoring, vaginal estrogen UTI treatment, menopause integrative care Texas, SSRIs SNRIs for hot flashes, cognitive behavioral therapy, clinical hypnosis, NK3RA, fezolinetant, women’s health